Clinical trials: PD-L1
Conjunctivitis, Allergic
Treg Effector Function and Th2/Treg Ratio in Allergic Conjunctivitis: Effect of Desensitization Therapy
This study aims to evaluate the effector function and expression of TIGIT and PD-1 on Tregs, as well as the Th2/Treg ratio, in patients with allergic conjunctivitis with and without desensitization therapy, compared to healthy…
- Trial name
- INMUNOREG (NCT07171307)
- Where
- Mexico
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Instituto de Oftalmología Fundación Conde de Valenciana
Non Small Cell Lung Cancer
Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC
Subjects will be eligible for this study if they are about to start on a drug called nivolumab for lung cancer. Some patients' cancers respond to nivolumab but a majority of patients do not.
- Trial name
- NO3DEXPL (NCT03371992)
- Testing
- Nivolumab, 3D-EX, Evaluation of Response by RECIST
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Nilogen Oncosystems
Non Small Cell Lung Cancer, Influenza Vaccine
Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
This project is to assess the immunogenicity, safety and overall survival impact of intramuscular injection of trivalent influenza vaccine in non-small cell lung cancer (NSCLC) patients with PD-1/PD-L1 inhibitor treatment.
- Trial name
- NCT04355806
- Testing
- PD-1/PD-L1 inhibitors, Inactivated trivalent influenza vaccine
- Where
- 2 sites in China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapies
Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study
To purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (PD-1 / PD-L1) combined with chemotherapy for locally advanced thoracic esophageal squamous cellcarcinoma.
- Trial name
- NICCE (NCT05028231)
- Testing
- Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
HNSCC
WGA in Platinum-refractory HNSCC Underwent Nivolumab
To choose a subgroup who could clearly benefit from Nivolumab, we are proposing a prospective observational study. Whole-genome study (WGS) analysis will be performed on archived cancer tissues from patients who were (1)…
- Trial name
- NCT03917537
- Testing
- HNSCC patients have used Nivolumab
- Where
- 2 sites in Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Lung Neoplasms
Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC
To evaluate the efficacy and safety of envafolimab combined with endostar in the first-line treatment of advanced Non-small Cell Lung Cancer With PD-L1 positive expression
- Trial name
- NCT05203276
- Testing
- Envafolimab, Endostar
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The First People's Hospital of Lianyungang
Prostate Cancer
PD-L1-expressing Regulatory T Cells in Localized Prostate Cancer Patients Undergoing Iodine-125 Permanent Brachytherapy
Immunotherapy is currently revolutionizing the field in oncology. However, prostate cancer is poorly responsive to immune checkpoint inhibition.
- Trial name
- NCT04369508
- Testing
- permanent brachytherapy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Lichen Planus
Assessment of PD-1 and PD-L1Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study
Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study
- Trial name
- NCT04892381
- Testing
- Skin Biopsy
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cairo University
Carcinoma, Non-Small-Cell Lung, Immunotherapy
Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)
This study was a French multicentric cross-sectional study retrospectively of 108 consecutive advanced NSCLC patients with a PD-L1 TPS ≥50% and without EGFR/ALK aberrations treated by pembrolizumab in first line.
- Trial name
- PEMBREIZH (NCT05321212)
- Where
- 2 sites in France
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
NSCLC Stage IV
Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients
Pembrolizumab is approved for advanced stage non-small cell lung cancer. However, the response rate is low (around 10-15 %) in patients treated in Macau SAR, China.
- Trial name
- NCT04076228
- Testing
- Pembrolizumab
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Kiang Wu Hospital
B-cell Malignancies
Expression of CD274 (PD-L1) and CD276 in B-cell Malignancies: A Study by Flowcytometry
B-cell malignancies include a spectrum of cancers originating from abnormal B lymphocytes at different developmental stages (1) that affect the peripheral blood (PB), bone marrow (BM), and lymphatic system.
- Trial name
- NCT07515313
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Assiut University
Sepsis, Immunosuppression
Expression and the Clinical Significance of Neutrophil PD-L1 During Sepsis
Immunosuppression is the leading cause of death in septic patients. Neutrophils are classical components of innate immunology, but recent studies showed that neutrophils might display antigen presenting function and inhibit…
- Trial name
- NCT01976884
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Circulating Tumor Cells (CTCs), Immunotherapy
Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores
Head and neck cancer is ranked among the fifth to eighth most prevalent cancers worldwide and is associated with a high mortality rate.
- Conditions
- Circulating Tumor Cells (CTCs), Immunotherapy, PD-L1 Expression, Liquidbiopsies
- Trial name
- NCT07396259
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Metastatic Triple-negative Breast Cancer
Saci Nivo Rela for TNBC
This is a randomized, open-label, phase Ib study to assess safety and efficacy of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus a fixed dose combination of nivolumab and relatlimab in patients with any…
- Trial name
- SIMONE (NCT06963905)
- Testing
- Relatlimab FDC + Nivolumab, Sacituzumab Govitecan (SG), Nivolumab
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yale University
Gastric Adenocarcinoma
Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance
Cadonilimab combined with paclitaxel (albumin-bound) treat advanced gastric adenocarcinoma or esophagogastric junction adenocarcinoma with PD-(L)1 inhibitors resistance
- Trial name
- NCT06118645
- Testing
- cadonilimab combined +paclitaxel (albumin-bound)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- China Medical University, China
Sepsis
PD-1/PD-L1 Pathway Study on Septic Patients
The investigators want to identify that whether PD-1/PD-L1 pathway will change in human sepsis, and whether PD-1/PD-L1 pathway play an important role in sepsis induced immunosuppression.
- Trial name
- NCT01161745
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Cancer, Immune System Disorder
Montreal Immune-Related Adverse Events (MIRAE) Study
Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in…
- Conditions
- Cancer, Immune System Disorder, Inflammatory Reaction, Autoimmune Diseases
- Trial name
- MIRAE (NCT05139706)
- Where
- Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Other Skin Changes Due to Chronic Exposure to Nonionizing Radiation
SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants
The purpose of this research study is to look at how the proteins and genes in people's skin change when they're exposed to simulated sunlight.
- Trial name
- NCT06177106
- Testing
- Solar Simulated Light
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Conventional biopsy and surgical tumor resection are invasive procedures that capture only one instance of the progression of the tumor. However, the genome of tumor is not static, but it is constantly altered during treatment.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma
- Trial name
- NCT04490564
- Testing
- PD-L1 Kit
- Where
- 6 sites in Greece
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Pharmassist Ltd
Head and Neck Squamous Cell Carcinoma, Circulating Tumor Cell
PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRT
Head and neck squamous cell carcinoma (HNSCC) is the 4th highest incidence of cancer and 6th of cancer death of the males in Taiwan.
- Trial name
- NCT05008796
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital